Understanding the future of Humira Biosimilar

Humira Biosimilar


Biosimilars are touted as the future of innovative biologic medicines, offering more affordable treatment options for patients worldwide. However, with the impending patent expiry of blockbuster drugs like Humira, there are still many unanswered questions about how the biosimilar market will evolve.


What are biosimilars?

Biosimilars are biologic medicines that are developed to be similar to an existing approved biologic drug, known as the reference product. They are engineered to be highly similar to the original biologic in terms of quality characteristics, biological activity, safety and efficacy. However, biosimilars are not generic copies of biologics. Developing a biosimilar is more challenging than a generic small molecule drug due to the complexity of biologics which are produced through living systems. Stringent regulatory requirements need to be fulfilled to demonstrate biosimilarity.

The first Humira biosimilar

Humira (adalimumab) developed by AbbVie is the highest selling drug globally. It generated over $20 billion in annual sales mainly treating autoimmune conditions like rheumatoid arthritis. Its patent expires in 2023 in the US and EU markets. However, the first Humira Biosimilar, Idacio, developed by Samsung Bioepis was approved by the European Medicines Agency (EMA) in August 2017. Other biosimilars are also under review. The approval of Idacio has set an important precedent and demonstrated the regulatory pathway for the approval of additional Humira biosimilars in key markets.

Impact on pricing and patient access

The introduction of Humira biosimilars is anticipated to significantly reduced drug costs and expand access to treatment. Experts estimate biosimilars could lower Humira's list price by 15-30%. This could translate to annual savings of $1-2 billion for the US healthcare system alone. Lower costs would allow more patients to initiate and maintain Humira therapy. For example, in Denmark where three Humira biosimilars are available, the uptake has increased to over 60% of all adalimumab prescriptions due to lower prices. Wider availability of biosimilars is expected to have a similar positive impact globally.

Challenges to achieve price reductions

However, there are concerns that not all the potential savings from biosimilars may be realised. Pharmaceutical companies use a variety of strategies to retain market share such as patient loyalty programs, copay cards and authorised generics sold at only slightly lower prices. Manufacturers of Humira have already launched these programs worth billions indicating they will face biosimilars aggressively. Regulatory issues like interchangeability status and restrictive formulary placement can reduce uptake and competition as well. Ongoing litigation between manufacturers may further delay biosimilar approvals and benefits for years. Overcoming these hurdles will be important for maximising the affordability impact of biosimilars.

Prospects for Humira biosimilars in the US

The US represents over 50% of Humira's global sales currently. But biosimilar approvals have come slowly in the US compared to Europe due to the complexity of the regulatory pathway. The first Humira biosimilar, Amjevita, was only approved in September 2016. Several others are under review but face patent litigation delays. It is anticipated wider availability of Humira biosimilars starting 2023 could lower the drug's US sales by $2-4 billion per year. However, the barriers highlighted previously may dampen uptake and competitive pressure on prices in the short term compared to a quicker uptake seen in some European markets. Over time, as more are approved and market dynamics evolve the full generic-like price reductions may be realised in the US as well.

Manufacturer strategies for the biosimilar era

Facing biosimilar competition, manufacturers are pursuing strategies to transition patients to newer product lines and indications. AbbVie is developing next-generation Humira formulations like adalimumab-adaz to extend market exclusivity. They are also investigating Humira for additional autoimmune and cancer indications. More approved uses would make switching to biosimilars logistically complex. In 2018, Humira's sales grew 16% year-over-year indicating these strategies are maintaining growth. As the adalimumab biosimilar market matures, an increasing proportion of global Humira sales will come from new territories, formulations and expanded label approvals. This ensures AbbVie sustains Humira's revenues despite impending patent expiry and biosimilar erosion.

Get More Insights on Humira Biosimilar

Comments

Post a Comment

Popular posts from this blog

Precision Medicine: Revolutionizing Cancer Diagnostics

Image
  Cancer Diagnostics Precision medicine, also known as personalized medicine, is a groundbreaking approach that tailors medical treatments to individual patients based on their unique genetic makeup, lifestyle, and environmental factors. It has emerged as a game-changer in the field of cancer diagnostics, revolutionizing the way we understand, diagnose, and treat cancer. By integrating cutting-edge technologies, precision medicine is paving the way for more accurate, effective, and targeted therapies, providing hope for patients and clinicians alike. Traditional Cancer Diagnostics and treatment approaches have often relied on a one-size-fits-all approach, assuming that patients with the same type of cancer would respond similarly to a given treatment. However, cancer is a highly heterogeneous disease, and each tumor can have distinct genetic alterations and molecular characteristics. Precision medicine acknowledges this complexity and seeks to uncover the unique drivers of each ...
Read more

Chromatography: A Recent Powerful Technique for separation of chemicals

Image
Chromatography Chromatography is a scientific technique used to separate the components of a mixture based on their chemical properties. Over the past century, it has evolved into a powerful analytical tool that is widely used across multiple disciplines for research, diagnostics, and quality control. What is Chromatography? Chromatography works on the principle that different components of a mixture move at different rates when transported between two phases, known as the stationary phase and the mobile phase. The stationary phase is a solid material such as alumina, silica, or a polymer, packed in a column. The mobile phase is a gas or liquid that carries the sample mixture through the column. As the mixture travels through the stationary phase, the individual components distribute themselves between the two phases based on their partitioning coefficients. Components that have a stronger interaction or affinity to the stationary phase will move slower through the column, while thos...
Read more

Unleashing Innovation: Healthcare Fabrics of Tomorrow

Image
  Healthcare Fabrics In recent years, the healthcare industry has been undergoing a profound transformation driven by technological advancements and a growing emphasis on patient-centric care. Among the various innovations that have gained attention is the development of advanced healthcare fabrics. These fabrics go beyond traditional medical textiles and have the potential to revolutionize patient care, infection control, comfort, and overall well-being. The Evolution of Healthcare Fabrics Healthcare fabrics have a long history, dating back centuries, when they were primarily used for bandages and dressing wounds. Over time, the focus shifted towards ensuring patient comfort and safety. Traditional healthcare fabrics were often utilitarian and sterile, designed for one-time use and limited functionality. However, with rapid technological progress and growing consumer demands, the healthcare industry recognized the need for more innovative solutions. This led to the developme...
Read more